With the July 2 PDUFA date approaching for Provention Bio’s (PRVB) breakthrough Type 1 Diabetes (T1D) therapy, I wanted to provide an update on what we should expect and how it could impact trading this week.
First things first…
New Data At 81st ADA Meeting
During a panel discussion at noon ET today at the American Diabetes Association’s (ADA) 81st annual meeting, entitled Teplizumab in Prevention and Response Profiles, we should get updated data from the pivotal TrialNet study.
You’ll recall, this is the study that instantly catapulted shares of Provention to $20+ when it was first released in June 2019.
Then, at last year’s ADA meeting, we got an update that Teplizumab delayed the onset of T1D by another year, on average.
I expect the same this year. We should see a chart with Kaplan-Meier curves like the ones below with the separation between the placebo and drug group continuing to widen.